We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
OBJECTIVES: Caelyx is a novel pegylated liposomal doxorubicin formulation and has been approved for the treatment of recurrent ovarian cancer. METHODS: We performed a multi-institutional phase-II study to analyze the toxicity profile of PLD (20mg/mZ/q 14d) in heavily pretreated patients with ROC. The study was supported by ESSEX Pharma, Germany. RESULTS: A(More)
  • 1